Any current/future new fundraising through debt or equity?

The company has a total CAPEX plan of Rs. 135 crores for the new ICD, with around Rs. 100 crores tied up via a loan from Canara Bank; the rest is funded through cash flow. For train replacements, an additional Rs. 150-200 crores CAPEX is planned this year, partially funded by loans. Debt is expected to increase by approximately Rs. 50 crores this year due to these CAPEX and train replacements. There is no explicit mention of new equity fundraising in the discussed sections. The company aims to repay loans ahead of schedule once cash flows improve, based on past history of early repayments. No

Any current/future capex/capital investment/strategic investment?

Ongoing CAPEX of ₹135 crores for new ICD facility at Morbi with ~40% completion (Page 5, 9, 12). Target to make ICD Morbi operational by Q3 FY 22-23 (around September-October 2022) (Page 5, 9,12). Additional ₹100 crore tied up with Canara Bank for Morbi project; remaining funded via cash flow (Page 9). Replacement of 12 leased trains with owned trains planned, improving operational efficiency and reducing costs (Page 8,14). Total capacity post-Morbi expected to be over 1 million TEUs; phased capacity addition and incremental revenue of ₹50 crores from Morbi anticipated in first year (Page 9, 1

Future growth expectations in sales/revenue/volumes?

Current utilization of 50% with a target to improve utilization by at least 10% annually. Capacity expected to increase to around 1 million TEUs after commissioning Morbi facility. Morbi ICD targeted to start operations by Q3 FY 22-23, with first-year revenue expected around Rs. 50 crores. Peak revenue from Morbi projected at Rs. 400 crores within 3-4 years. Capacity utilization growth driven by domestic, EXIM, and cross-selling business across Mumbai, Vapi, and Morbi locations. Anticipated gradual increase in volumes aligned with government policies and easing container availability. Replacem

Future growth expectations in earnings/operating earnings/profits/EPS?

The company targets around 10% annual growth in capacity utilization from current ~50%. After Morbi ICD becomes operational (targeting Q3 FY22-23), revenue is expected to increase by ₹50 crores in the first year. Peak revenue from Morbi is projected at around ₹400 crores within 3-4 years. Operating margin (EBITDA) targeted to improve from current ~24% to around 30% over the next 2-3 years. Ownership of trains (replacing leased) expected to save approximately ₹2.5 crores annually and improve operational efficiency. Benefits from government schemes (Gati Shakti, DFCC) expected to enhance profita

Current/ Expected Orderbook/ Pending Orders?

The transcript does not provide explicit details on the current or expected order book or pending orders in numeric terms. However, the company is actively targeting new customers daily and expanding its operations across multiple facilities, including Mumbai, Vapi, and the upcoming Morbi ICD. They have engaged with over 2,000 clients in Morbi across tile, paper, and chemical industries. The company aims to grow its capacity utilization gradually by at least 10% annually. Revenue targets include approximately Rs 50 crore additional revenue from the new Morbi ICD in the first year and a peak re

Navkar Corporat.Q4 FY22

Navkar Corporat. Q4 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹85.1P/E: 33.2Market Cap: ₹1.3K Cr

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Current utilization of 50% with a target to improve utilization by at least 10% annually.
Capacity expected to increase to around 1 million TEUs after commissioning Morbi facility.
Morbi ICD targeted to start operations by Q3 FY 22-23, with first-year revenue expected around Rs. 50 crores.
Peak revenue from Morbi projected at Rs. 400 crores within 3-4 years.
Capacity utilization growth driven by domestic, EXIM, and cross-selling business across Mumbai, Vapi, and Morbi locations.
Anticipated gradual increase in volumes aligned with government policies and easing container availability.
Replacement of lease trains with owned trains expected to improve operational efficiency and margins.
Overall target to grow EBITDA margins by approximately 20% considering new initiatives like Gati Shakti and Morbi operations.

Margin guidance

Category 1

The company targets around 10% annual growth in capacity utilization from current ~50%.
After Morbi ICD becomes operational (targeting Q3 FY22-23), revenue is expected to increase by ₹50 crores in the first year.
Peak revenue from Morbi is projected at around ₹400 crores within 3-4 years.
Operating margin (EBITDA) targeted to improve from current ~24% to around 30% over the next 2-3 years.
Ownership of trains (replacing leased) expected to save approximately ₹2.5 crores annually and improve operational efficiency.
Benefits from government schemes (Gati Shakti, DFCC) expected to enhance profitability by 20% in a couple of years.
Diesel price hikes partly passed to customers; no major margin impact anticipated going forward.
Overall steady and gradual earnings growth is expected, with no extraordinary growth forecast but stable improvements.

See what Navkar Corporat. management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company has a total CAPEX plan of Rs. 135 crores for the new ICD, with around Rs. 100 crores tied up via a loan from Canara Bank; the rest is funded through cash flow.
For train replacements, an additional Rs. 150-200 crores CAPEX is planned this year, partially funded by loans.
Debt is expected to increase by approximately Rs. 50 crores this year due to these CAPEX and train replacements.
There is no explicit mention of new equity fundraising in the discussed sections.
The company aims to repay loans ahead of schedule once cash flows improve, based on past history of early repayments.
No direct comment on future equity issuance; focus is on utilizing loans and cash flows for expansion and repayments.

Order book

The transcript does not provide explicit details on the current or expected order book or pending orders in numeric terms.
However, the company is actively targeting new customers daily and expanding its operations across multiple facilities, including Mumbai, Vapi, and the upcoming Morbi ICD.
They have engaged with over 2,000 clients in Morbi across tile, paper, and chemical industries.
The company aims to grow its capacity utilization gradually by at least 10% annually.
Revenue targets include approximately Rs 50 crore additional revenue from the new Morbi ICD in the first year and a peak revenue of around Rs 400 crore over the next 3-4 years.
The management expects capacity utilization to improve post Morbi operations and the operationalization of schemes like Gati Shakti and DFCC, which will further boost business and margins.

See what Navkar Corporat. management said on order book — free account, 30 seconds.

Capex plans

Yes

Ongoing CAPEX of ₹135 crores for new ICD facility at Morbi with ~40% completion (Page 5, 9, 12).
Target to make ICD Morbi operational by Q3 FY 22-23 (around September-October 2022) (Page 5, 9,12).
Additional ₹100 crore tied up with Canara Bank for Morbi project; remaining funded via cash flow (Page 9).
Replacement of 12 leased trains with owned trains planned, improving operational efficiency and reducing costs (Page 8,14).
Total capacity post-Morbi expected to be over 1 million TEUs; phased capacity addition and incremental revenue of ₹50 crores from Morbi anticipated in first year (Page 9, 12).
Focus on strategic growth via Morbi, Vapi ICD facilities, and cross-selling to improve margins up to ~30% over 2-3 years (Page 9, 12, 14).
Further CAPEX plans depend on business growth and government policies like Gati Shakti and Dedicated Freight Corridor (Page 8,11,14).

Track Navkar Corporat. — get its next earnings analysis in your feed

How does Navkar Corporat. rank vs peers in ?

Pro feature

ThisNavkar Corporat.

Rev 3Mar 1

See where Navkar Corporat. sits in See which companies these are, and every other name in the sector.Open rankings

What Navkar Corporat.'s management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →